- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes, 212Pb-PSMA / Orano, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
Uncovering the mechanisms of action of 177Lu- and 212Pb- based PSMA radioligand therapies (Section 6; Poster Board No: 6) - Mar 25, 2025 - Abstract #AACR2025AACR_4875;
Comparison studies of 177Lu- and 212Pb-PSMA treatment on PC cells showed a higher efficacy of 212Pb-PSMA in vitro and in vivo supporting the clinical application of 212Pb-PSMA for mCRPC. Mechanistic studies furthered the understanding of PC radiobiology and cellular responses to beta- and alpha-RLT with the identification of a cell cycle arrest in PC specifically induced by 212Pb-PSMA.
- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes
212Pb SPECT/CT Clinical Imaging for Routine Biodistribution and Dosimetry of Targeted Alpha Therapy (Hall F) - Sep 27, 2024 - Abstract #EANM2024EANM_1433;
We have developed a SPECT/CT acquisition protocol for routine biodistribution and dosimetry imaging in patients with metastatic castration resistant prostate cancer (mCRPC) following the administration of a novel PSMA-targeted-therapy, [212Pb] Pb-ADVC001... 212Pb SPECT/CT imaging allows confirmation of TAT biodistribution and permits TAT dose estimates, assuming no progeny redistribution.
- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes
Novel 212Pb-PSMA Targeted Alpha Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer (Hall X1-X4) - Sep 27, 2024 - Abstract #EANM2024EANM_1056;
P1/2
Preclinical pharmacokinetic, biodistribution and efficacy data demonstrate the potential of 212Pb-PSMA for the treatment of mCRPC. In vivo, improved efficacy with more durable responses is observed with 212Pb-ADVC001 compared to 177Lu-PSMA I&T suggesting that 212Pb-ADVC001 has the potential to not only limit toxicities associated with conventional PSMA-targeted radiopharmaceuticals, but also to improve treatment of mCRPC.
- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Phase Ib/IIa Dose Escalation and Expansion Study of [ (clinicaltrials.gov) - Jul 30, 2024
P1/2, N=100, Recruiting,
In vivo, improved efficacy with more durable responses is observed with 212Pb-ADVC001 compared to 177Lu-PSMA I&T suggesting that 212Pb-ADVC001 has the potential to not only limit toxicities associated with conventional PSMA-targeted radiopharmaceuticals, but also to improve treatment of mCRPC. N=18 --> 100 | Trial completion date: Jun 2024 --> Dec 2029 | Trial primary completion date: Jun 2024 --> Dec 2027
- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes
Trial completion date, Trial primary completion date, Metastases: Phase Ib/IIa Dose Escalation and Expansion Study of [ (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=18, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- |||||||||| 212 Pb-ADVC001 / AdvanCell Isotopes
Enrollment open, Metastases: Phase Ib/IIa Dose Escalation and Expansion Study of [ (clinicaltrials.gov) - Mar 17, 2023
P1/2, N=18, Recruiting,
Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Not yet recruiting --> Recruiting
|
